{"entity":{"id":"nct07125872","kind":"trial","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","aka":[],"tldr":"A phase 2 trial of CD19 t-haNK in non-Hodgkin lymphoma, run by ImmunityBio, Inc., now recruiting.","summary":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma is a phase 2 interventional study registered as NCT07125872 by ImmunityBio, Inc., with 20 participants planned, started 2025-11-11 and due to reach its primary completion in 2027-05-25. Interventions recorded: CD19 t-haNK- IV Administration.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07125872","url":"https://clinicaltrials.gov/study/NCT07125872"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cd19-t-hank"],"companies":["immunitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07125872","phase":"2","setting":"Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","sponsor":"ImmunityBio, Inc.","enrolled":20,"outcomes":[]},"route":"/trials/nct07125872/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/"}],"company":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"}]}}